The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
FDA grants annamycin Investigational New Drug Application approval for treatment of R/R AML
On 26th September 2017, the U.S. Food and Drug Administration (FDA) granted Investigational New Drug (IND) application approval for annamycin, an anthracycline antibiotic, for the treatment of patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML).1 This IND approval comes after the Orphan Drug Designation granted by the FDA and the recent IND application, which the AGP reported in March and August respectively.
Current anthracyclines such as doxorubicin used in standard chemotherapy for AML patients are associated with risk of cardiotoxicity as well as drug resistance.2 Annamycin (liposomal annamycin) is a liposome-encapsulated form of the anthracycline doxorubicin, with antineoplastic activity. Annamycin evades cellular Multidrug-Resistance (MDR) mechanisms and eliminates cardiotoxicity.3
The IND approval granted by the FDA allows annamycin to be evaluated in R/R AML patients in clinical trials. Moleculin, the drug manufacturers noted that the trial aims to evaluate the potential of annamycin in becoming the “first 2nd line therapy suitable for the majority” of R/R AML patients.1
The FDA IND approval also allows the drug manufacturers to make a submission to the Polish authorities which is required for a planned phase I/II clinical trial with annamycin to be conducted in Poland.1
References
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?